Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
BPC 157 may mitigate the damaging consequences of spinal cord contusion, improving neuronal survival and functional outcomes following such injuries
The closest human evidence in its drug class is Athira Pharma's fosgonimeton (ATH-1017), a structurally distinct molecule in the same HGF/c-Met program whose Phase 2/3 LIFT-AD Alzheimer's trial failed its primary endpoint in September 2024 (GST 0.08, P=.70)
Much of the online conversation focuses on whether BPC-157 works
Peptides represent marginal gains
It supports gut health, protects against NSAID damage, and promotes recovery from various types of tissue injury
US$ 20.28
US$ 25.69
US$ 26.02
US$ 29.81
US$ 22.78
US$ 22.09
US$ 21.11
US$ 22.78
